During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Luciano Costa, University of Alabama at Birmingham, Birmingham, US. We asked: Can daratumumab (dara) overcome the negative prognostic impact of high-risk cytogenetics?
Dara has impacted the lives of patients with both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory disease. However, the clinical activity of dara is yet to be determined in patients with NDMM and high-risk cytogenetics.
At this year's virtual EHA Annual Congress, results will be presented from a meta analysis of patients with high-risk cytogenetics treated in trials evaluating an MM backbone treatment ± dara. Here, Luciano Costa highlights the benefit of dara observed in this setting and other key results.